Live Breaking News & Updates on Corbus pharmaceuticals company profile

Stay informed with the latest breaking news from Corbus pharmaceuticals company profile on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Corbus pharmaceuticals company profile and stay connected to the pulse of your community

Corbus Pharmaceuticals (NASDAQ:CRBP) Downgraded to Sell at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Downgraded to Sell at StockNews.com
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Mirae-asset-global-investments-co , Securities-exchange-commission , Corbus-pharmaceuticals-holdings-inc , Corbus-pharmaceuticals , Jefferies-financial-group , Corbus-pharmaceuticals-price-performance , Nasdaq , News-ratings-for-corbus-pharmaceuticals-daily , Corbus-pharmaceuticals-company-profile , Exchange-commission , Get-free-report

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded at Jefferies Financial Group

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded at Jefferies Financial Group
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Blackrock , Nova-scotia , News-ratings-for-corbus-pharmaceuticals-daily , Royal-bank , Jefferies-financial-group , Vident-investment-advisory , Hedge-funds-weigh-in-on-corbus-pharmaceuticals , Dimensional-fund-advisors , Corbus-pharmaceuticals-company-profile , Corbus-pharmaceuticals-price-performance

Corbus Pharmaceuticals (NASDAQ:CRBP) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning. Separately, Oppenheimer upped their price objective on shares of Corbus Pharmaceuticals from $20.00 to $51.00 and gave the company an outperform rating in a research note on […]

News-ratings-for-corbus-pharmaceuticals-daily , Corbus-pharmaceuticals-company-profile , Vident-investment-advisory , Corbus-pharmaceuticals , Institutional-trading-of-corbus-pharmaceuticals , Corbus-pharmaceuticals-price-performance , Securities-exchange-commission , Corbus-pharmaceuticals-holdings-inc , Blackrock-inc , Dimensional-fund-advisors , Renaissance-technologies

Oppenheimer Raises Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $51.00

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]

Corbus-pharmaceuticals-holdings-inc , Corbus-pharmaceuticals , Institutional-investors-weigh-in-on-corbus-pharmaceuticals , Corbus-pharmaceuticals-company-profile , Corbus-pharmaceuticals-trading , News-ratings-for-corbus-pharmaceuticals-daily , Vident-investment-advisory , Securities-exchange-commission , Renaissance-technologies , Dimensional-fund-advisors , Free-report

Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Hold Rating from Analysts at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Hold Rating from Analysts at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Corbus-pharmaceuticals , Blackrock-inc , Renaissance-technologies , Corbus-pharmaceuticals-stock-down , Dimensional-fund-advisors , News-ratings-for-corbus-pharmaceuticals-daily , Sio-capital-management , Corbus-pharmaceuticals-holdings-inc , Corbus-pharmaceuticals-company-profile , Get-free-report , Pharmaceuticals-stock-down

Corbus Pharmaceuticals (NASDAQ:CRBP) Coverage Initiated by Analysts at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Coverage Initiated by Analysts at StockNews.com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sio-capital-management , Corbus-pharmaceuticals , Corbus-pharmaceuticals-company-profile , Hedge-funds-weigh-in-on-corbus-pharmaceuticals , Corbus-pharmaceuticals-holdings-inc , Vident-investment-advisory , Renaissance-technologies , Corbus-pharmaceuticals-price-performance , News-ratings-for-corbus-pharmaceuticals-daily , Free-report , Get-free-report

Corbus Pharmaceuticals (NASDAQ:CRBP) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. Corbus Pharmaceuticals Stock Performance Corbus Pharmaceuticals stock opened at $5.25 on Friday. Corbus Pharmaceuticals has a 52 week low of $2.11 and a […]

Corbus-pharmaceuticals-holdings-inc , Corbus-pharmaceuticals-stock-performance , Vident-investment-advisory , Renaissance-technologies , Corbus-pharmaceuticals-company-profile , Hedge-funds-weigh-in-on-corbus-pharmaceuticals , Sio-capital-management , Corbus-pharmaceuticals , News-ratings-for-corbus-pharmaceuticals-daily , Free-report , Get-free-report

Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Corbus-pharmaceuticals , Corbus-pharmaceuticals-stock-down , Corbus-pharmaceuticals-holdings-inc , Virtu-financial , News-ratings-for-corbus-pharmaceuticals-daily , Corbus-pharmaceuticals-company-profile , Dimensional-fund-advisors , Hedge-funds-weigh-in-on-corbus-pharmaceuticals , Vident-investment-advisory , Get-free-report , Pharmaceuticals-stock-down

Corbus Pharmaceuticals (NASDAQ:CRBP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report sent to investors on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, Oppenheimer reissued an outperform rating and set a $22.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday, August […]

Hedge-funds-weigh-in-on-corbus-pharmaceuticals , News-ratings-for-corbus-pharmaceuticals-daily , Vident-investment-advisory , Corbus-pharmaceuticals , Blackrock-inc , Dimensional-fund-advisors , Corbus-pharmaceuticals-company-profile , Virtu-financial , Corbus-pharmaceuticals-holdings-inc , Corbus-pharmaceuticals-price-performance , Free-report

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 65,400 shares, a decrease of 13.3% from the August 31st total of 75,400 shares. Currently, 1.5% of the shares of the company are sold short. […]

Vident-investment-advisory , Institutional-trading-of-corbus-pharmaceuticals , Nasdaq , News-ratings-for-corbus-pharmaceuticals-daily , Corbus-pharmaceuticals , Corbus-pharmaceuticals-holdings-inc , Renaissance-technologies , Sio-capital-management , Corbus-pharmaceuticals-price-performance , Corbus-pharmaceuticals-company-profile , Corbus-pharmaceuticals-holdings